149 related articles for article (PubMed ID: 21750727)
1. Genetic variation on 9p22 is associated with abnormal ovarian ultrasound results in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
Wentzensen N; Black A; Jacobs K; Yang HP; Berg CD; Caporaso N; Peters U; Ragard L; Buys SS; Chanock S; Hartge P
PLoS One; 2011; 6(7):e21731. PubMed ID: 21750727
[TBL] [Abstract][Full Text] [Related]
2. Functional Analysis and Fine Mapping of the 9p22.2 Ovarian Cancer Susceptibility Locus.
Buckley MA; Woods NT; Tyrer JP; Mendoza-Fandiño G; Lawrenson K; Hazelett DJ; Najafabadi HS; Gjyshi A; Carvalho RS; Lyra PC; Coetzee SG; Shen HC; Yang AW; Earp MA; Yoder SJ; Risch H; Chenevix-Trench G; Ramus SJ; Phelan CM; Coetzee GA; Noushmehr H; Hughes TR; Sellers TA; Goode EL; Pharoah PD; Gayther SA; Monteiro ANA;
Cancer Res; 2019 Feb; 79(3):467-481. PubMed ID: 30487138
[TBL] [Abstract][Full Text] [Related]
3. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial.
Buys SS; Partridge E; Greene MH; Prorok PC; Reding D; Riley TL; Hartge P; Fagerstrom RM; Ragard LR; Chia D; Izmirlian G; Fouad M; Johnson CC; Gohagan JK;
Am J Obstet Gynecol; 2005 Nov; 193(5):1630-9. PubMed ID: 16260202
[TBL] [Abstract][Full Text] [Related]
4. Genetic variation in innate immunity and inflammation pathways associated with lung cancer risk.
Shiels MS; Engels EA; Shi J; Landi MT; Albanes D; Chatterjee N; Chanock SJ; Caporaso NE; Chaturvedi AK
Cancer; 2012 Nov; 118(22):5630-6. PubMed ID: 23044494
[TBL] [Abstract][Full Text] [Related]
5. Genetic variation in catechol-O-methyltransferase (COMT) and obesity in the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial.
Wang SS; Morton LM; Bergen AW; Lan EZ; Chatterjee N; Kvale P; Hayes RB; Chanock SJ; Caporaso NE
Hum Genet; 2007 Aug; 122(1):41-9. PubMed ID: 17497175
[TBL] [Abstract][Full Text] [Related]
6. Pathologic findings following false-positive screening tests for ovarian cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial.
Nyante SJ; Black A; Kreimer AR; Duggan MA; Carreon JD; Kessel B; Buys SS; Ragard LR; Johnson KA; Dunn BK; Lamerato L; Commins JM; Berg CD; Sherman ME
Gynecol Oncol; 2011 Mar; 120(3):474-9. PubMed ID: 21144559
[TBL] [Abstract][Full Text] [Related]
7. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2.
Song H; Ramus SJ; Tyrer J; Bolton KL; Gentry-Maharaj A; Wozniak E; Anton-Culver H; Chang-Claude J; Cramer DW; DiCioccio R; Dörk T; Goode EL; Goodman MT; Schildkraut JM; Sellers T; Baglietto L; Beckmann MW; Beesley J; Blaakaer J; Carney ME; Chanock S; Chen Z; Cunningham JM; Dicks E; Doherty JA; Dürst M; Ekici AB; Fenstermacher D; Fridley BL; Giles G; Gore ME; De Vivo I; Hillemanns P; Hogdall C; Hogdall E; Iversen ES; Jacobs IJ; Jakubowska A; Li D; Lissowska J; Lubiński J; Lurie G; McGuire V; McLaughlin J; Medrek K; Moorman PG; Moysich K; Narod S; Phelan C; Pye C; Risch H; Runnebaum IB; Severi G; Southey M; Stram DO; Thiel FC; Terry KL; Tsai YY; Tworoger SS; Van Den Berg DJ; Vierkant RA; Wang-Gohrke S; Webb PM; Wilkens LR; Wu AH; Yang H; Brewster W; Ziogas A; ; ; ; Houlston R; Tomlinson I; Whittemore AS; Rossing MA; Ponder BA; Pearce CL; Ness RB; Menon U; Kjaer SK; Gronwald J; Garcia-Closas M; Fasching PA; Easton DF; Chenevix-Trench G; Berchuck A; Pharoah PD; Gayther SA
Nat Genet; 2009 Sep; 41(9):996-1000. PubMed ID: 19648919
[TBL] [Abstract][Full Text] [Related]
8. Assessing the risk of ovarian malignancy in asymptomatic women with abnormal CA 125 and transvaginal ultrasound scans in the prostate, lung, colorectal, and ovarian screening trial.
Partridge EE; Greenlee RT; Riley TL; Commins J; Ragard L; Xu JL; Buys SS; Prorok PC; Fouad MN
Obstet Gynecol; 2013 Jan; 121(1):25-31. PubMed ID: 23262924
[TBL] [Abstract][Full Text] [Related]
9. Replication study for the association of seven genome- GWAS-identified Loci with susceptibility to ovarian cancer in the Polish population.
Mostowska A; Sajdak S; Pawlik P; Markowska J; Pawałowska M; Lianeri M; Jagodzinski PP
Pathol Oncol Res; 2015 Apr; 21(2):307-13. PubMed ID: 25173882
[TBL] [Abstract][Full Text] [Related]
10. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.
Prorok PC; Andriole GL; Bresalier RS; Buys SS; Chia D; Crawford ED; Fogel R; Gelmann EP; Gilbert F; Hasson MA; Hayes RB; Johnson CC; Mandel JS; Oberman A; O'Brien B; Oken MM; Rafla S; Reding D; Rutt W; Weissfeld JL; Yokochi L; Gohagan JK;
Control Clin Trials; 2000 Dec; 21(6 Suppl):273S-309S. PubMed ID: 11189684
[TBL] [Abstract][Full Text] [Related]
11. Overall and Multiphasic Findings of the Prostate, Lung, Colorectal and Ovarian (PLCO) Randomized Cancer Screening Trial.
Prorok PC; Wright P; Riley TR; Kramer BS; Berg CD; Gohagan JK
Rev Recent Clin Trials; 2018; 13(4):257-273. PubMed ID: 29629665
[TBL] [Abstract][Full Text] [Related]
12. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status.
Gohagan JK; Prorok PC; Hayes RB; Kramer BS;
Control Clin Trials; 2000 Dec; 21(6 Suppl):251S-272S. PubMed ID: 11189683
[TBL] [Abstract][Full Text] [Related]
13. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24.
Goode EL; Chenevix-Trench G; Song H; Ramus SJ; Notaridou M; Lawrenson K; Widschwendter M; Vierkant RA; Larson MC; Kjaer SK; Birrer MJ; Berchuck A; Schildkraut J; Tomlinson I; Kiemeney LA; Cook LS; Gronwald J; Garcia-Closas M; Gore ME; Campbell I; Whittemore AS; Sutphen R; Phelan C; Anton-Culver H; Pearce CL; Lambrechts D; Rossing MA; Chang-Claude J; Moysich KB; Goodman MT; Dörk T; Nevanlinna H; Ness RB; Rafnar T; Hogdall C; Hogdall E; Fridley BL; Cunningham JM; Sieh W; McGuire V; Godwin AK; Cramer DW; Hernandez D; Levine D; Lu K; Iversen ES; Palmieri RT; Houlston R; van Altena AM; Aben KK; Massuger LF; Brooks-Wilson A; Kelemen LE; Le ND; Jakubowska A; Lubinski J; Medrek K; Stafford A; Easton DF; Tyrer J; Bolton KL; Harrington P; Eccles D; Chen A; Molina AN; Davila BN; Arango H; Tsai YY; Chen Z; Risch HA; McLaughlin J; Narod SA; Ziogas A; Brewster W; Gentry-Maharaj A; Menon U; Wu AH; Stram DO; Pike MC; ; Beesley J; Webb PM; ; ; ; Chen X; Ekici AB; Thiel FC; Beckmann MW; Yang H; Wentzensen N; Lissowska J; Fasching PA; Despierre E; Amant F; Vergote I; Doherty J; Hein R; Wang-Gohrke S; Lurie G; Carney ME; Thompson PJ; Runnebaum I; Hillemanns P; Dürst M; Antonenkova N; Bogdanova N; Leminen A; Butzow R; Heikkinen T; Stefansson K; Sulem P; Besenbacher S; Sellers TA; Gayther SA; Pharoah PD;
Nat Genet; 2010 Oct; 42(10):874-9. PubMed ID: 20852632
[TBL] [Abstract][Full Text] [Related]
14. Inherited variation in circadian rhythm genes and risks of prostate cancer and three other cancer sites in combined cancer consortia.
Gu F; Zhang H; Hyland PL; Berndt S; Gapstur SM; Wheeler W; Ellipse Consortium T; Amos CI; Bezieau S; Bickeböller H; Brenner H; Brennan P; Chang-Claude J; Conti DV; Doherty JA; Gruber SB; Harrison TA; Hayes RB; Hoffmeister M; Houlston RS; Hung RJ; Jenkins MA; Kraft P; Lawrenson K; McKay J; Markt S; Mucci L; Phelan CM; Qu C; Risch A; Rossing MA; Wichmann HE; Shi J; Schernhammer E; Yu K; Landi MT; Caporaso NE
Int J Cancer; 2017 Nov; 141(9):1794-1802. PubMed ID: 28699174
[TBL] [Abstract][Full Text] [Related]
15. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.
Buys SS; Partridge E; Black A; Johnson CC; Lamerato L; Isaacs C; Reding DJ; Greenlee RT; Yokochi LA; Kessel B; Crawford ED; Church TR; Andriole GL; Weissfeld JL; Fouad MN; Chia D; O'Brien B; Ragard LR; Clapp JD; Rathmell JM; Riley TL; Hartge P; Pinsky PF; Zhu CS; Izmirlian G; Kramer BS; Miller AB; Xu JL; Prorok PC; Gohagan JK; Berg CD;
JAMA; 2011 Jun; 305(22):2295-303. PubMed ID: 21642681
[TBL] [Abstract][Full Text] [Related]
16. Randomization to screening for prostate, lung, colorectal and ovarian cancers and thyroid cancer incidence in two large cancer screening trials.
O'Grady TJ; Kitahara CM; DiRienzo AG; Boscoe FP; Gates MA
PLoS One; 2014; 9(9):e106880. PubMed ID: 25192282
[TBL] [Abstract][Full Text] [Related]
17. Potential effect of the risk of ovarian cancer algorithm (ROCA) on the mortality outcome of the Prostate, Lung, Colorectal and Ovarian (PLCO) trial.
Pinsky PF; Zhu C; Skates SJ; Black A; Partridge E; Buys SS; Berg CD
Int J Cancer; 2013 May; 132(9):2127-33. PubMed ID: 23065684
[TBL] [Abstract][Full Text] [Related]
18. Overall mortality in men and women in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
Pinsky PF; Miller EA; Zhu CS; Prorok PC
J Med Screen; 2019 Sep; 26(3):127-134. PubMed ID: 30943843
[No Abstract] [Full Text] [Related]
19. Cumulative incidence of false-positive results in repeated, multimodal cancer screening.
Croswell JM; Kramer BS; Kreimer AR; Prorok PC; Xu JL; Baker SG; Fagerstrom R; Riley TL; Clapp JD; Berg CD; Gohagan JK; Andriole GL; Chia D; Church TR; Crawford ED; Fouad MN; Gelmann EP; Lamerato L; Reding DJ; Schoen RE
Ann Fam Med; 2009; 7(3):212-22. PubMed ID: 19433838
[TBL] [Abstract][Full Text] [Related]
20. The role of transvaginal ultrasound in screening for ovarian cancer.
Campbell S; Gentry-Maharaj A
Climacteric; 2018 Jun; 21(3):221-226. PubMed ID: 29490504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
